Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease

Petra Mlcochova, Dami Collier, Allyson Ritchie, Sonny M. Assennato, Myra Hosmillo, Neha Goel, Bo Meng, Krishna Chatterjee, Vivien Mendoza, Nigel Temperton, Leo Kiss, Leo C. James, Katarzyna A. Ciazynska, Xiaoli Xiong, John AG Briggs, James Nathan, Federica Mescia, Hongyi Zhang, Petros Barmpounakis, Nikos Demeris, Richard Skells, Paul A. Lyons, John Bradley, Steven Baker, Jean Pierre Allain, Kenneth GC Smith, Ian Goodfellow, View ORCID ProfileRavindra K. Gupta
doi: https://doi.org/10.1101/2020.06.16.20133157
Petra Mlcochova
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dami Collier
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
3Division of Infection and Immunity, University College London, UK. WC1E 6BT
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Allyson Ritchie
4Diagnostics for the Real World EU Ltd., Chesterford Research Park, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sonny M. Assennato
4Diagnostics for the Real World EU Ltd., Chesterford Research Park, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Myra Hosmillo
5Department of Pathology, University of Cambridge, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neha Goel
4Diagnostics for the Real World EU Ltd., Chesterford Research Park, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bo Meng
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Krishna Chatterjee
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vivien Mendoza
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nigel Temperton
7Viral Pseudotype Unit, Medway School of Pharmacy, University of Kent, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo Kiss
8Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Leo C. James
8Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Katarzyna A. Ciazynska
8Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoli Xiong
8Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John AG Briggs
8Medical Research Council Laboratory of Molecular Biology, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Nathan
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Federica Mescia
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongyi Zhang
9Clinical Microbiology & Public Health Laboratory, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Petros Barmpounakis
10Department of Statistics, Athens University of Economics and Business, Athens, Greece
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nikos Demeris
10Department of Statistics, Athens University of Economics and Business, Athens, Greece
11Cambridge Clinical Trials Unit-Cancer Theme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Skells
6NIHR Cambridge Clinical Research Facility, Cambridge, UK
11Cambridge Clinical Trials Unit-Cancer Theme
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Lyons
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John Bradley
3Division of Infection and Immunity, University College London, UK. WC1E 6BT
12National Institutes for Health Research Cambridge Biomedical Research Centre, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven Baker
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Pierre Allain
4Diagnostics for the Real World EU Ltd., Chesterford Research Park, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kenneth GC Smith
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ian Goodfellow
5Department of Pathology, University of Cambridge, Cambridge
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ravindra K. Gupta
1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
13Department of Infectious Diseases, Cambridge University NHS Hospitals Foundation Trust, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ravindra K. Gupta
  • For correspondence: rkg20@cam.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Rapid COVID-19 diagnosis in hospital is essential for patient management and identification of infectious patients to limit the potential for nosocomial transmission. The diagnosis of infection is complicated by 30-50% of COVID-19 hospital admissions with nose/throat swabs testing negative for SARS-CoV-2 nucleic acid, frequently after the first week of illness when SARS-CoV-2 antibody responses become detectable. We assessed the diagnostic accuracy of combined rapid antibody point of care (POC) and nucleic acid assays for suspected COVID-19 disease in the emergency department.

Methods We developed (i) an in vitro neutralization assay using a lentivirus expressing a genome encoding luciferase and pseudotyped with spike (S) protein and (ii) an ELISA test to detect IgG antibodies to nucleocapsid (N) and S proteins from SARS-CoV-2. We tested two lateral flow rapid fingerprick tests with bands for IgG and IgM. We then prospectively recruited participants with suspected moderate to severe COVID-19 and tested for SARS-CoV-2 nucleic acid in a combined nasal/throat swab using the standard laboratory RT-PCR and a validated rapid POC nucleic acid amplification (NAAT) test. Additionally, serum collected at admission was retrospectively tested by in vitro neutralisation, ELISA and the candidate POC antibody tests. We evaluated the performance of the individual and combined rapid POC diagnostic tests against a composite reference standard of neutralisation and standard laboratory based RT-PCR.

Results 45 participants had specimens tested for nucleic acid in nose/throat swabs as well as stored sera for antibodies. Using the composite reference standard, prevalence of COVID-19 disease was 53.3% (24/45). Median age was 73.5 (IQR 54.0-86.5) years in those with COVID-19 disease by our composite reference standard and 63.0 (IQR 41.0-72.0) years in those without disease. The overall detection rate against the composite reference standard was 79.2% (95CI 57.8-92.9%) for rapid NAAT, decreasing from 100% (95% CI 65.3-98.6%) in days 1-4 to 50.0% (95% CI 11.8-88.2) for days 9-28 post symptom onset. Correct identification of COVID-19 with combined rapid POC diagnostic tests was 100% (95CI 85.8-100%) with a false positive rate of 5.3-14.3%, driven by POC LFA antibody tests.

Conclusions Combined POC tests have the potential to transform our management of COVID-19, including inflammatory manifestations later in disease where nucleic acid test results are negative. A rapid combined approach will also aid recruitment into clinical trials and in prescribing therapeutics, particularly where potentially harmful immune modulators (including steroids) are used.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04326387

Funding Statement

RKG is supported by a Wellcome Trust Senior Fellowship in Clinical Science (WT108082AIA). DAC is supported by a Wellcome PhD training Fellowship. This research was supported by the National Institute for Health Research (NIHR) Cambridge Biomedical Research Centre and the Cambridge Clinical Trials Unit (CCTU). LCJ is supported by the MRC (UK; U105181010) and a Wellcome Investigator Award. JAGB is supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme (ERC-CoG-648432 MEMBRANEFUSION), and the Medical Research Council (MC_UP_1201/16).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

COVIDx, NCT04326387 was approved by the East of England Essex Research Ethics Committee (REC ref: 20/EE/0109). Serum samples were obtained from patients attending Addenbrookes Hospital with a suspected or confirmed diagnosis of COVID19. Ethical approval was obtained from the East of England Cambridge Central Research Ethics Committee REC ref 17/EE/0025.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The CITIID-NIHR COVID BioResource Collaboration

  • Principal Investigators: Stephen Baker, John Bradley, Gordon Dougan, Ian Goodfellow, Ravi Gupta, Paul J. Lehner, Paul Lyons, Nicholas J. Matheson, Kenneth G.C. Smith, Mark Toshner, Michael P. Weekes

  • Clinical Microbiology & Public Health Laboratory (PHE): Nick Brown, Martin Curran, Surendra Palmar, Hongyi Zhang, David Enoch.

  • Institute of Metabolic Science, University of Cambridge Daniel Chapman

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK Ashley Shaw

  • NIHR Cambridge Clinical Research Facility: Sherly Jose, Areti Bermperi, Julie Ann Zerrudo, Evgenia Kourampa, Laura Watson, Jieniean Worsley, Caroline Saunders, Ranalie de Jesus, Jason Domingo, Ciro Pasquale, Bensi Vergese, Phoebe Vargas, Marivic Fabiculana, Marlyn Perales

  • Cambridge Cancer Trial Centre: Lee Mynott, Elizabeth Blake, Amy Bates, Anne-Laure Vallier, Alexandra Williams, David Phillips, Edmund Chiu, Alex Overhill, Nicola Ramenatte, Jamal Sipple, Steven Frost, Helena Knock, Richard Hardy, Emily Foster, Fiona Davidson,Viona Rundell, Purity Bundi, Richmond Abeseabe, Sarah Clark, Isabel Vicente, Laura Watson, Jieniean Worsley

  • CRF and Volunteer Research Nurses Anne Elmer, Carla Ribeiro, Jenny Kourampa, Sherly Jose, Jane Kennet, Jane Rowlands, Anne Meadows, Criona O’Brien, Rebecca Rastall, Cherry Crucusio, Sarah Hewitt, Jane Price, Jo Calder, Laura Canna, Ashlea Bucke, Hugo Tordesillas, Julie Harris, Valentina Ruffolo, Jason Domingo, Barbara Graves, Helen Butcher, Daniela Caputo and Emma Le Gresley

  • Sample Logistics Benjamin J Dunmore, Jennifer Martin, Ekaterina Legchenko, Carmen Treacy, Christopher Huang, Jennifer Wood, Rachel Sutcliffe, Josh Hodgson, Joy Shih, Stefan Graf, Zhen Tong, Federica Mescia, Tobias Tilly, Ciara O’Donnell, Kelvin Hunter, Linda Pointon, Nicole Pond, Marta Wylot, Emma Jones, Stuart Fawke and Ben Bullman

  • Sample Acquisition and Processing Laura Bergamaschi, Lori Turner, Isobel Jarvis, Ommar Omarjee, Aloka De Sa, Joe Marsden, Ariana Betancourt, Marianne Perera, Maddie Epping, Nathan Richoz, Georgie Bower, Rahul Sharma, Francesca Nice, Oisin Huhn, Stuart Fawke, Natalia Savoinykh Yarkoni, Nika Romashova, Daniel Lewis, Andrew Hinch, Chiara Cossetti, Mateusz Strezlecki, Richard Grenfell.

  • NIHR BioResource Hannah Stark, Neil Walker, Kathy Stirrups, Nigel Ovington, Eleanor Dewhust, Emily Li and Sofia Papadia

Data Availability

Data are available on request from the corresponding author

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted June 26, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease
Petra Mlcochova, Dami Collier, Allyson Ritchie, Sonny M. Assennato, Myra Hosmillo, Neha Goel, Bo Meng, Krishna Chatterjee, Vivien Mendoza, Nigel Temperton, Leo Kiss, Leo C. James, Katarzyna A. Ciazynska, Xiaoli Xiong, John AG Briggs, James Nathan, Federica Mescia, Hongyi Zhang, Petros Barmpounakis, Nikos Demeris, Richard Skells, Paul A. Lyons, John Bradley, Steven Baker, Jean Pierre Allain, Kenneth GC Smith, Ian Goodfellow, Ravindra K. Gupta
medRxiv 2020.06.16.20133157; doi: https://doi.org/10.1101/2020.06.16.20133157
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Combined point of care SARS-CoV-2 nucleic acid and antibody testing in suspected moderate to severe COVID-19 disease
Petra Mlcochova, Dami Collier, Allyson Ritchie, Sonny M. Assennato, Myra Hosmillo, Neha Goel, Bo Meng, Krishna Chatterjee, Vivien Mendoza, Nigel Temperton, Leo Kiss, Leo C. James, Katarzyna A. Ciazynska, Xiaoli Xiong, John AG Briggs, James Nathan, Federica Mescia, Hongyi Zhang, Petros Barmpounakis, Nikos Demeris, Richard Skells, Paul A. Lyons, John Bradley, Steven Baker, Jean Pierre Allain, Kenneth GC Smith, Ian Goodfellow, Ravindra K. Gupta
medRxiv 2020.06.16.20133157; doi: https://doi.org/10.1101/2020.06.16.20133157

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (141)
  • Anesthesia (44)
  • Cardiovascular Medicine (408)
  • Dentistry and Oral Medicine (67)
  • Dermatology (47)
  • Emergency Medicine (141)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4809)
  • Forensic Medicine (3)
  • Gastroenterology (177)
  • Genetic and Genomic Medicine (670)
  • Geriatric Medicine (70)
  • Health Economics (187)
  • Health Informatics (621)
  • Health Policy (314)
  • Health Systems and Quality Improvement (200)
  • Hematology (84)
  • HIV/AIDS (155)
  • Infectious Diseases (except HIV/AIDS) (5279)
  • Intensive Care and Critical Care Medicine (325)
  • Medical Education (91)
  • Medical Ethics (24)
  • Nephrology (73)
  • Neurology (677)
  • Nursing (41)
  • Nutrition (110)
  • Obstetrics and Gynecology (124)
  • Occupational and Environmental Health (203)
  • Oncology (437)
  • Ophthalmology (138)
  • Orthopedics (36)
  • Otolaryngology (88)
  • Pain Medicine (35)
  • Palliative Medicine (15)
  • Pathology (127)
  • Pediatrics (193)
  • Pharmacology and Therapeutics (129)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (766)
  • Public and Global Health (1796)
  • Radiology and Imaging (321)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (68)
  • Sports Medicine (61)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (28)
  • Urology (37)